Pharma's Almanac

28 Articles Available

1 2

IND, NDA, and BLA

Building a Regulatory Roadmap for IND, NDA, and BLA

PAO-03-24-CL-10

Nice Insight API Report

Small Molecule API Discovery and Development Trends

PAO-03-24-NI-01

mRNA–LNP Manufacturing

The Innovators Bringing Continuous Manufacturing to Lipid Nanoparticles

PAO-03-24-CL-08

Radioconjugate development

Expediting Radioimmune Conjugate Pharmaceuticals for First-In-Human Phase 0 Proof-of-Concept Human Studies from Stable Pool

PAO-03-24-CL-07

Viral Vectors

A Viral Vector CDMO Vision that Resonates

PAO-03-24-CL-06

Analytical Method Development

Harnessing Biologic Development Experience in Support of CDMO Clients: Rapid, Effective and Tailored Analytical Method Development

PAO-03-24-CL-09

Clinical Trials Representation

Leveraging Decentralized Clinical Trial Strategies to Reduce Health Care Disparities

PAO-03-24-CL-05

Commitment to ESG Principles

How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?

PAO-03-24-CL-03

Accelerating Product Development

What strategies are being employed to accelerate product development and commercialization without compromising quality?

PAO-03-24-CL-02

Bispecific Antibodies

Accelerating the Development and Production of High-Quality Bispecific Antibodies

PAO-03-24-CL-01

Pediatric Clinical Trials

Pediatric Clinical Trials: Considerations for Enrollment and Retention

PAO-02-24-CL-04

Digital Pathology

Advancing Disease Research and Drug Development on an Enterprise Pathology Software Platform

PAO-01-24-CL-2

Portable CMC

Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use

PR-M02-29-01

Advanceability

Right from the Start: Designing Advanceable Formulations and Processes at Phase I

PAO-02-24-CL-09

3D Printing

Exploring New Possibilities with 3D Printing of Pharmaceuticals

PAO-02-24-CL-11

CDMO - Small Biotech

Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility

PAO-02-24-CL-07

Tech Transfer

Transparent Communication Supports Tech Transfers Of Cis-targeted Immunotherapies

PAO-02-24-CL-06

Biologics Formulation

Successful Formulation Development for Biologics Using a Unique Biophysical Prediction and Screening Platform

PAO-02-24-CL-02

Translation

The Translational Index Score: Improving the Entire Drug Development Cycle

PAO-02-24-CL-10

Cell-Free

Cell-Free Protein Synthesis Holds Real Potential to Transform Drug Development and Manufacturing

PAO-02-24-NI-01

Robotic Sterile Fill-Finish

Reducing Time to First-in-Human Trials with Robotic Sterile Fill-Finish Manufacturing Services

PAO-02-24-CL-03

Synthetic DNA

Is Synthetic Plasmid DNA One of the Solutions for Meeting Growing Demand for Next-Gen Therapies?

PAO-01-24-NI-04

Genomics

Integrated Spatial Genomics: Real Potential to Provide Truly Novel Biological Insights

PAO-01-24-NI-03

CDMO

Advanced Technologies Unlocking the Future of Drug Manufacturing

PAO-03-24-CL-04

1 2

Q12024